Please login to the form below

Not currently logged in
Email:
Password:

Chugai profits may exceed forecast

Chugai, the Japanese subsidiary of Swiss pharmaceutical company Roche, may exceed its own profits forecast

Chugai, the Japanese subsidiary of Swiss pharmaceutical company Roche, may exceed its own profits forecast, according to Mitsubishi UFJ securities analysts.

Chugai's net income rose 8.5 per cent in Q3 FY07, which means that the company may meet its target for operating profit of JPY 100bn (USD 872m) by 2010, say the analysts.

Epogin, which is Chugai's best-selling product, increased its share of the Japanese market for anaemia drugs to 62 per cent. The company reduced the drug's price in Japan in July 2007 in order to compete effectively with Kirin's own product Nesp. Later in August, the company suggested it might not meet its profit target because of increased competition and the end of a marketing agreement with French pharmaceutical company sanofi-aventis.

The analysts said that Epogin Q1 FY07 sales were not as badly affected by Nesp as Chugai first thought. They added that the company could reach its target of operating profit by 2011, if not before.

Chugai's shares increased 5.3 per cent (JPY 95) to reach JPY 1,897 on the Tokyo Stock Exchange on 24 October.

A survey of 16 analysts by Bloomberg revealed that Chugai's net income could hit JPY 36.7bn for FY07. In July 2007, the company forecast FY07 profit of JPY 33.5bn, a fall on the FY06 profit of JPY 38.4bn.

For Q3 FY07, Chugai posted net income of JPY 9.1bn, compared with JPY 8.4bn in Q3 FY06, according to Bloomberg.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics